Glutamatergic neurotransmission in schizophrenia: A systematic review and quantitative synthesis of proton magnetic resonance spectroscopy studies across schizophrenia spectrum disorders
Open Access
- 29 May 2024
- journal article
- review article
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 58 (11) , 930-951
Abstract
Objective: Studies using proton magnetic resonance spectroscopy reveal substantial inconsistencies in the levels of brain glutamate, glutamine and glutamate + glutamine across schizophrenia spectrum disorders. This systematic review employs qualitative and quantitative methods to analyse the patterns and relationships between glutamatergic metabolites, schizophrenia spectrum disorders and brain regions. Methods: A literature search was conducted using various databases with keywords including glutamate, glutamine, schizophrenia, psychosis and proton magnetic resonance spectroscopy. Inclusion criteria were limited to case-control studies that reported glutamatergic metabolite levels in adult patients with a schizophrenia spectrum disorder diagnosis – i.e. first-episode psychosis, schizophrenia, treatment-resistant schizophrenia and/or ultra-treatment-resistant schizophrenia – using proton magnetic resonance spectroscopy at 3 T or above. Pooled study data were synthesized and analysed. Results: A total of 92 studies met the inclusion criteria, including 2721 healthy controls and 2822 schizophrenia spectrum disorder participants. Glu levels were higher in the basal ganglia, frontal cortex and medial prefrontal of first-episode psychosis participants, contrasting overall lower levels in schizophrenia participants. For Gln, strong differences in metabolite levels were evident in the basal ganglia, dorsolateral prefrontal cortex and frontal cortex, with first-episode psychosis showing significantly higher levels in the basal ganglia. In glutamate + glutamine, higher metabolite levels were found across schizophrenia spectrum disorder groups, particularly in the basal ganglia and dorsolateral prefrontal cortex of treatment-resistant schizophrenia participants. Significant relationships were found between metabolite levels and medication status, clinical measures and methodological variables. Conclusion: The review highlights abnormal glutamatergic metabolite levels throughout schizophrenia spectrum disorders and in specific brain regions. The review underscores the importance of standardized future research assessing glutamatergic metabolites using proton magnetic resonance spectroscopy due to considerable literature heterogeneity.Keywords
Funding Information
- National Health and Medical Research Council (GNT1154651)
This publication has 39 references indexed in Scilit:
- Medial Prefrontal Cortex Glutamate Is Reduced in Schizophrenia and Moderated by Measurement Quality: A Meta-analysis of Proton Magnetic Resonance Spectroscopy StudiesBiological Psychiatry, 2021
- Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate LevelJAMA Psychiatry, 2021
- Association of Cortical Glutamate and Working Memory Activation in Patients With Schizophrenia: A Multimodal Proton Magnetic Resonance Spectroscopy and Functional Magnetic Resonance Imaging StudyBiological Psychiatry, 2020
- The impact of endurance training and table soccer on brain metabolites in schizophreniaBrain Imaging and Behavior, 2019
- Optimized in vivo brain glutamate measurement using long‐echo‐time semi‐LASER at 7 TNMR in Biomedicine, 2018
- Nature of Glutamate Alterations in SchizophreniaJAMA Psychiatry, 2016
- Increased Glutamine in Patients Undergoing Long-term Treatment for SchizophreniaJAMA Psychiatry, 2014
- Elevated Prefrontal Cortex γ-Aminobutyric Acid and Glutamate-Glutamine Levels in Schizophrenia Measured In Vivo With Proton Magnetic Resonance SpectroscopyArchives of General Psychiatry, 2012
- Brain Metabolite Abnormalities in the White Matter of Elderly Schizophrenic Subjects: Implication for Glial DysfunctionBiological Psychiatry, 2007
- Atypical antipsychotics and the relevance of glutamate and serotoninEuropean Neuropsychopharmacology, 2004